Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27384353 | 0.76 | DHODH (0.35) | PTGS2NPC1ALDH1A1CYP2A6CASP3 | |
| SCHEMBL12921979 | 0.73 | NPC1 (0.38) | KMT2ANPC1CYP3A4CYP2C19KDM4E | |
| SCHEMBL14883234 | 0.72 | GABRA1 (0.33) | PDPK1NPC1GABRA1GABRB2CYP3A4 | |
| SCHEMBL11497551 | 0.72 | TP53 (0.43) | PTGS2KMT2ATP53ALOX15MAPK1 | |
| SCHEMBL27379003 | 0.72 | CYP2A6 (0.37) | CYP3A4CYP2C19CYP2E1CYP2D6CYP2A6 | |
| SCHEMBL1821918 | 0.71 | CYP2A6 (0.60) | PTGS2KMT2ATP53ALOX15MAPK1 | |
| SCHEMBL1681771 | 0.69 | PTGS2 (0.65) | PTGS2PTPRC | |
| SCHEMBL3316273 | 0.68 | KMT2A (0.42) | PTGS2KMT2ATP53ALOX15MAPK1 | |
| SCHEMBL26176500 | 0.68 | ALOX5 (0.38) | PTGS2KMT2ATP53MAPK1NPC1 | |
| SCHEMBL20033971 | 0.68 | TDO2 (0.40) | PTGS2ALOX15GABRA1GABRB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839144-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210217973-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | UNIV ARIZONA STATE (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210205291-A1 | NITROGENOUS HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-11011712-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20180226593-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-08-09 | — | — | US | disclosed |
| US-9941479-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| WO-2017121969-A1 | NOVEL PHOSPHINANE AND AZAPHOSPHINANE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2017-07-20 | — | — | WO | disclosed |
| US-9365614-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2016-06-14 | — | — | US | disclosed |
| US-20140336134-A1 | IAP BIR Domain Binding Compounds | PHARMASCIENCE INC. (CA) | 2014-11-13 | — | — | US | disclosed |
| US-8765681-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-7547724-B2 | IAP BIR domain binding compounds | AEGERA THERPEUTICS, INC. | 2009-06-16 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | AEGERA THERAPEUTICS, INC. (CA) | 2008-03-20 | — | — | US | disclosed |
| US-20080014207-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2008-01-17 | — | — | US | disclosed |
| US-20070219140-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-09-20 | — | — | US | disclosed |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180226593-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | DPYD, DCTD, TYMP | PTGS2 3525/4885KMT2A 3281/4885TP53 260/4885 |
| US-11011712-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | DPYD, DCTD, TYMP | PTGS2 3525/4885KMT2A 3281/4885TP53 260/4885 |
| US-20070093429-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | PTGS2 3826/4885KMT2A 4686/4885TP53 18/4885 |
| US-20080014207-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | PTGS2 3826/4885KMT2A 4686/4885TP53 18/4885 |
| US-20210217973-A1 | Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues | DPYD, DCTD, TYMP | PTGS2 3525/4885KMT2A 3281/4885TP53 260/4885 |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | BAD, BIRC5, BAX | PTGS2 3438/4885KMT2A 4730/4885TP53 22/4885 |
| US-20140336134-A1 | IAP BIR Domain Binding Compounds | BIRC2, BIRC7, BIRC5 | PTGS2 3762/4885KMT2A 4496/4885TP53 78/4885 |
| US-20070219140-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC8 | PTGS2 3813/4885KMT2A 4661/4885TP53 20/4885 |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | BIRC5, XIAP, BIRC2 | PTGS2 3176/4885KMT2A 4399/4885TP53 14/4885 |
| US-20210205291-A1 | NITROGENOUS HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION | NNT, NAPRT, NAT1 | PTGS2 614/4885KMT2A 3374/4885TP53 3581/4885 |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | PTGS2 4275/4885KMT2A 3594/4885TP53 7/4885 |
| US-11839144-B2 | Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues | DPYD, DCTD, TYMP | PTGS2 3525/4885KMT2A 3281/4885TP53 260/4885 |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | BIRC5, XIAP, BAX | PTGS2 3036/4885KMT2A 4542/4885TP53 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.